Therapeutic antibodies

IIBR's Antibody engineering group developed three antibody-based therapeutics to be used against chemical and biological threat agents such as: Anthrax, ricin, organophosphates, botulinum and Tularemia.
LSRI filed patent applications for these antibodies, both in the US and in Israel.
LSRI intends to license the patent and its rights to use, to international companies for further development in clinical level

Write to us

We welcome you to contact us for any question or offer for collaborations.

Required Full name Field Enter your full name please.

Required Phone prefix Field International phone prefix Error

Required Phone Field Enter your phone number.

Required Email Field There is an error in your input e-mail address.

There is an error in your input Message.

the mail is recived, thank you